{
    "nctId": "NCT00216021",
    "briefTitle": "Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "- To determine the objective response rate (CR+PR) of capecitabine and oxaliplatin (CAPOX) in patients with metastatic breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic or cytologic diagnosis of breast cancer with evidence of (1) unresectable, locally recurrent, or (2) metastatic disease.\u00b7\n* Patients with HER2 positive (3+ overexpression by IHC or gene amplification by FISH) are eligible only if they have had prior trastuzumab therapy.\u00b7\n* At least one measurable lesion as defined by the RECIST.\n* Prior radiation therapy is allowed as long as the irradiated area is not the only source of measurable disease.\n\nExclusion Criteria:\n\n* No prior therapy with capecitabine or oxaliplatin in any setting\n* No prior therapy with other platinum compounds\u00b7\n* No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to beginning protocol therapy.\u00b7\n* No prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.\u00b7\n* No prior fluoropyrimidine therapy for metastatic disease is allowed. Prior adjuvant fluoropyrimidine therapy is allowed if completed \\> 12 months from study entry.\u00b7\n* Maximum of one prior chemotherapy regimen for unresectable, locally recurrent or metastatic disease\u00b7\n* No symptomatic brain metastasis. \u00b7\n* No evidence of serious concomitant systemic disorders incompatible with the study \u00b7\n* No peripheral neuropathy \u00b7\n* No major surgery within 28 days prior to beginning protocol therapy.\u00b7\n* Negative pregnancy test\u00b7\n* No female patients currently breastfeeding\u00b7\n* No malabsorption syndrome\u00b7\n* No evidence of serious concomitant systemic disorders incompatible with the study\u00b7\n* Patients must not be treated with any of the following while on protocol therapy or within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine, allopurinol.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}